At Obsidian, we are pioneering a new generation of engineered cell and gene therapies. Our proprietary cytoDRiVE® platform leverages drug responsive domains (DRDs) to control protein function using an FDA-approved small molecule.
Engineer gene cassette for therapeutic protein with DRD tag; package & insert into cell
Cell produces fusion protein with unfolded DRD tag that is rapidly degraded by proteasome (basal function is OFF)
Addition of FDA-approved small molecule ligand stabilizes DRD; protein is expressed and accumulates to functional levels in a titratable & reversible manner